SCHEMBL20914941

SCHEMBL20914941

CCCCC(CCC)NC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 2/20 0.51
TAS1R3 Q7RTX0 6/20 0.44
TAS1R1 Q7RTX1 6/20 0.44
CA2 P00918 3/20 0.43
MAPK1 P28482 1/20 0.43
DPP7 Q9UHL4 3/20 0.43
DPP4 P27487 2/20 0.43
DPP8 Q6V1X1 2/20 0.43
DPP9 Q86TI2 2/20 0.43
ENPP2 Q13822 1/20 0.40
SLC15A1 P46059 1/20 0.40
CA1 P00915 2/20 0.39
CHRM1 P11229 1/20 0.39
AKR1A1 P14550 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064012 0.92 PLA2G2C (0.53) PLA2G2CPLA2G10
SCHEMBL4856257 0.91 PLA2G2C (0.56) PLA2G2CCA2MAPK1DPP7PLA2G10
SCHEMBL5133204 0.91 TAS1R3 (0.50) PLA2G2CTAS1R3TAS1R1CHRM1AKR1A1
SCHEMBL10437284 0.89 PLA2G2C (0.59) PLA2G2CCA2PLA2G10
SCHEMBL4856599 0.89 PLA2G2C (0.59) PLA2G2CCA2PLA2G10
SCHEMBL5953705 0.89 PLA2G2C (0.59) PLA2G2CCA2PLA2G10
SCHEMBL22722954 0.88 PLA2G2C (0.49) PLA2G2CTAS1R3TAS1R1CA2MAPK1
SCHEMBL5469229 0.88 TAS1R3 (0.42) PLA2G2CTAS1R3TAS1R1CHRM1AKR1A1
SCHEMBL22722955 0.88 PLA2G2C (0.49) PLA2G2CTAS1R3TAS1R1CA2MAPK1
SCHEMBL20459227 0.87 PLA2G2C (0.56) PLA2G2CPLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2019-11-19 US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CA PLA2G2C 260/4885TAS1R3 1413/4885TAS1R1 704/4885
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PLA2G2C 434/4885TAS1R3 3467/4885TAS1R1 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.